Trial · NCT07883161
Targeted Nutritional Intervention (HMB, Arginine, Glutamine) in Patients With Pancreatic Cancer
NCT07883161, Not applicable, Not yet recruiting, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Targeted Nutritional Intervention (HMB, Arginine, Glutamine) in Patients With Pancreatic Cancer. Trials, record NCT07883161. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07883161
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Targeted Nutritional Intervention (HMB, Arginine, Glutamine) in Patients With Pancreatic Cancer
- NCT number
- NCT07883161
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 24 participants, estimated
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Conditions
- PDAC, Pancreas Adenocarcinoma (MSI-H)
- Interventions
- HMB / L-Arginine / L-Glutamine oral nutritional mixture, Standard Dietary Counseling
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in Skeletal Muscle Index (SMI) at Day 60 | Baseline (Day 0) and Day 60 | Skeletal Muscle Index (SMI) is calculated from cross-sectional abdominal computed tomography (CT) images at the third lumbar vertebra (L3) level using densitometric muscle area segmentation normalized for height squared (cm²/m²). The primary outcome measure evaluates the difference in SMI between baseline (T0, prior to intervention initiation) and Day 60 (T60). |
| Secondary | Change from Baseline in Muscle Radiation Attenuation and Adipose Depots at Day 60 | Baseline (Day 0) and Day 60 | Radiologic assessment via abdominal CT scan at the L3 level to quantify myosteatosis measured as Mean Muscle Attenuation in Hounsfield Units (HU). |
| Secondary | Change from Baseline in Isometric Handgrip Strength at Day 60 | Baseline (Day 0) and Day 60 | Handgrip strength assessed using a calibrated digital dynamometer, measured in kilograms (kg), recording the average/maximum across dominant-hand trials. |
| Secondary | Change from Baseline in Short Physical Performance Battery (SPPB) Total Score at Day 60 | Baseline (Day 0) and Day 60 | Physical capacity will be measured via the SPPB composite score combining gait speed, balance testing, and chair-rise test. Total score ranges from 0 to 12 points, with higher scores reflecting better functional status and performance. |
| Secondary | Change from Baseline in Prognostic Nutritional Index at Day 60 | Baseline (Day 0) and Day 60 | Prognostic Nutritional Index (PNI) will be calculated using albumin and lymphocyte levels |
| Secondary | Overall Survival (OS) Rate at 6 and 12 Months | Assessed at 6 and 12 months from enrollment | OS: Percentage of participants alive from the date of enrollment to the designated follow-up timepoints. |
| Secondary | Progression-Free Survival (PFS) Rate at 6 and 12 Months | Assessed at 6 and 12 months from enrollment | PFS: Percentage of participants without objective radiological disease progression (according to standard RECIST criteria) or death from any cause. |
| Secondary | Change from Baseline in Patient-Reported Quality of Life (EORTC QLQ-C30) at Day 60 | Baseline (Day 0) and Day 60 | Multidimensional assessment evaluated through validated instruments: EORTC QLQ-C30 (core oncology questionnaire; scores 0-100). Higher functional scores indicate better function; higher symptom scores indicate worse symptom severity. |
| Secondary | Change from Baseline in Disease-Specific Symptoms (EORTC QLQ-PAN26) at Day 60 | Baseline (Day 0) and Day 60 | Pancreatic cancer-specific symptoms and side effects assessed using the EORTC QLQ-PAN26 module, comprising 26 items covering disease-specific symptoms (e.g., pain, digestive issues, cachexia-related signs). Scores are linearly converted to a 0 to 100 scale, where higher scores represent greater symptom severity/burden. |
| Secondary | Change from Baseline in Patient-Change from Baseline in Cachexia-Related Quality of Life (EORTC QLQ-CAX24) at Day 60 | Baseline (Day 0) and Day 60 | Cancer cachexia-specific symptom burden and psychosocial impact assessed using the EORTC QLQ-CAX24 module, consisting of 24 items evaluating cachexia-related eating difficulties, food worries, and physical decline. Scores are linearly transformed to a 0 to 100 scale, with higher scores reflecting worse cachexia-related symptoms and impact. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07883161
GET https://conductscience.org/api/trials/v1/NCT07883161/registered